Last update 21 Nov 2024

Ad-HGF(The First Affiliated Hospital with Nanjing Medical University)

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Gene therapy

Synonyms-

Target-

Mechanism

Gene transference

Therapeutic Areas

Cardiovascular Diseases

Active Indication-

Inactive Indication

Myocardial Infarction

Originator Organization

Third Affiliated Hospital of Nanjing Medical University

Active Organization-

Inactive Organization

Third Affiliated Hospital of Nanjing Medical University

Drug Highest PhasePendingPhase 1/2

First Approval Date-

Regulation-

Clinical Trials associated with Ad-HGF(The First Affiliated Hospital with Nanjing Medical University)

NCT02844283 / Unknown statusPhase 1/2IIT

Adenovirus Carrying Hepatocyte Growth Factor (Ad-HGF) Treatment for Myocardial Infarction

This will be the first clinical trial use Ad-HGF gene for the treatment of myocardial infarction disease.

Start Date01 Nov 2016

Sponsor / Collaborator

Third Affiliated Hospital of Nanjing Medical University

100 Clinical Results associated with Ad-HGF(The First Affiliated Hospital with Nanjing Medical University)

100 Translational Medicine associated with Ad-HGF(The First Affiliated Hospital with Nanjing Medical University)

100 Patents (Medical) associated with Ad-HGF(The First Affiliated Hospital with Nanjing Medical University)

Literatures (Medical) associated with Ad-HGF(The First Affiliated Hospital with Nanjing Medical University)

01 Sep 2023·Ophthalmology Science

Aerosolized, Gas-Phase, Intravitreal Methotrexate Reduces Proliferative Vitreoretinopathy in a Randomized Trial in a Porcine Model

Article

Author: Naqwi, Amir ; Asheim, Collin G ; Schmit, Jenn ; Salomao, Diva R ; Olsen, Timothy W ; Hann, Cheryl R ; Wabner, Kathy

PurposeTo determine the effectiveness of aerosol-delivered methotrexate (AD-MTx) in a large-animal (porcine) model of proliferative vitreoretinopathy (PVR).DesignProspective, randomized, interventional, double-masked, controlled, large-animal study with predetermined clinical and histopathologic outcome criteria.ControlsHalf of the pigs were randomly assigned to receive an identical volume of aerosol-delivered normal saline (AD-NS) using identical delivery systems and treatment intervals.MethodsProliferative vitreoretinopathy was surgically induced in 16 pigs (8 males and 8 females), randomly assigned to receive 2 doses (group A) or 3 doses (group B) of either AD-MTx (1.6 mg/0.4 ml) or normal saline (AD-NS). Group A pigs were euthanized at week 2 (n = 8), and group B pigs were euthanized at week 3 (n = 8). Masked clinical PVR scores (0-6) by a vitreoretinal surgeon and histopathology PVR scores (0-8) by a masked ophthalmic pathologist were used to determine outcomes.Main Outcome MeasuresThe mean, combined clinical and histopathology scores (both anterior and posterior) were used to determine the overall treatment effect between the groups.ResultsThe mean masked score (± standard deviation) when all grading end points (clinical + histopathology) were combined was a mean of 8.0 ± 2.3 in the AD-MTx group versus a higher 9.9 ± 2.0 in the AD-NS control group (P = 0.05). The clinical score was 3.88 ± 1.2 in the AD-MTx group versus 4.63 ± 1.6 in the AD-NS group (P = 0.16). The histopathology score for anterior PVR was 2.5 ± 0.8 in the AD-MTx group versus 2.5 ± 0.5 in the AD-NS group (P = 0.50), and the posterior PVR was 1.63 ± 1.6 in the AD-MTx group versus 2.75 ± 1.3 in the AD-NS group (P = 0.07). When the frequency of methotrexate dosing in group A (2 doses) was compared with that in group B (3 doses), the mean score was 8.75 versus 9.13 (P = 0.38), respectively, suggesting an insignificant difference.ConclusionsAfter surgical induction of PVR in an aggressive, high-risk, large-animal model, AD-MTx reduced posterior PVR formation compared with AD-NS. Additional dosing at week 3 did not improve the outcomes. No difference in anterior PVR formation was noted with intervention. This novel drug delivery system has implications for PVR reduction and warrants further investigation.Financial DisclosuresProprietary or commercial disclosure may be found after the references.

01 Sep 2022·Journal of Orthopaedic Surgery

Achyranthoside D (AD) improve intervertebral disc degeneration through affect the autophagy and the activation of PI3K/Akt/mTOR pathway

Article

Author: Yang, Shaofeng ; Li, Linghui ; Li, Shuofu ; Zhang, Xiao ; Chen, Long ; Li, Zhaoyong ; Zhang, Chao ; Yang, Lei ; Guo, Yantao

Purpose This study aims to explore the potential mechanism of Achyranthoside D (AD) in improving intervertebral disc (IVD) degeneration (IDD). Methods The IDD model of SD rats and nucleus pulposus cells (NPCs) was established by lumbar cone annulus puncture and tert-butyl peroxide, respectively. Cell proliferation was detected by CCK8 assay. Apoptosis was detected by flow cytometry and TUNEL staining. IVD tissue injury was observed by HE staining. Alcian blue staining observed the glycoprotein secretion in IVD. Monodansylcadaverin (MDC) staining was used to detect the formation of autophagosomes. The LC3 expression was tested by immunofluorescence. The type II collagen, aggrecan and MMP3 expression were detected by ELISA. RT-qPCR was used to detect the Casp 3, Bax, Bcl2, Acan, Col2a1 and Mmp3 expression. The LC3, P62, type II collagen, aggrecan, Beclin1, Akt, MMP3, p-mTOR, PI3K, mTOR, p-PI3K and p-Akt expression were analyzed by western blot. Results The IVD tissue damage and apoptosis occurred in the Model group, and the glycoprotein secretion decreased. Compared with Model group, AD-H group alleviated the injury of IVD tissue, inhibited the apoptosis of cells, and increased the secretion of glycoprotein. 40 μg/mL AD restored the proliferation activity of NPCs. Compared to the Normal group, the NPCs apoptosis increased, the Collagen II, aggrecan and Bcl2 expressions were significantly decreased, the MMP3, Bax and Casp 3 expression were significantly increased, and the LC-3 II/I expression in IVD tissues were increased significantly in Model group, all of which was reversed in AD group. AD promoted the p-Akt, p-PI3K, p-mTOR, LC-3 II/I and Beclin1 expression, inhibited the P62 expression to alleviate the damage of nucleus pulporeus cells and the degeneration of IVD. Conclusion AD improved IDD by affecting the PI3K/Akt/mTOR pathway and autophagy.

01 Jan 2021·Journal of Allergy and Clinical ImmunologyQ1 · MEDICINE

Unique skin abnormality in patients with peanut allergy but no atopic dermatitis

Q1 · MEDICINE

Article

Author: Leung, Donald Y M ; Hoffman, Bryce C ; Elias, Peter M ; Crumrine, Debra ; Berdyshev, Evgeny ; Goleva, Elena ; Bronova, Irina ; Garcia, Shannon L ; Bronoff, Anna-Sofia ; Cho, Christine B ; Ramirez-Gama, Marco A

BACKGROUNDThe nonlesional skin of children with atopic dermatitis (AD) with peanut allergy (PA) is associated with increased transepidermal water loss; low urocanic acid (UCA) and pyrrolidone carboxylic acid (PCA), both of which are filaggrin breakdown products; and a reduced ratio of esterified ω-hydroxy fatty acid sphingosine ceramides (EOS-CERs) to nonhydroxy fatty acid sphingosine ceramides (NS-CERs) in the skin. The skin barrier of subjects with PA without AD (AD^-PA⁺) has not been studied.OBJECTIVEOur aim was to explore whether AD^-PA⁺ is associated with skin barrier abnormalities.METHODSA total of 33 participants were enrolled, including 13 AD^-PA⁺, 9 AD⁺PA⁺, and 11 nonatopic (NA) participants.RESULTSThe PCA content in the stratum corneum of AD^-PA⁺ subjects was significantly reduced versus that in NA subjects (median level, 67 vs 97 μg/mg protein [P = .028]). The ratio between cis- and trans-UCA decreased significantly from being highest in the NA group (1.62) to lowest in AD⁺PA⁺ group (0.07 [P < .001 vs in the NA group; P = .006 vs in the AD^-PA⁺ group]), with the AD^-PA⁺ group having an intermediate cis/trans-UCA ratio (1.17 [P = .024 vs in the NA group]). The TEWL in AD^-PA⁺ subjects did not differ from that in the group with NA skin. Interestingly, AD^-PA⁺ subjects had an increased EOS/NS-CER ratio versus that in the group of subjects with NA skin (1.9 vs 1.3 [P = .008]), whereas the AD⁺PA⁺ group had a decreased proportion of EOS-CERs (0.8 [P = .001] vs in the AD^-PA⁺ group).CONCLUSIONOur data demonstrate that irrespective of AD, PA is associated with decreased skin cis-UCA and PCA content. An increase in skin EOS-CER/NS-CER ratio separates the AD^-PA⁺ group from the AD⁺PA⁺ and NA groups.

100 Deals associated with Ad-HGF(The First Affiliated Hospital with Nanjing Medical University)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Myocardial Infarction	Phase 2	-	Third Affiliated Hospital of Nanjing Medical University	01 Nov 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Ad-HGF(The First Affiliated Hospital with Nanjing Medical University)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation